Heartland NCORP sites implement drive-through laboratory service

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Two component institutions of Heartland Cancer Research NCORP have created drive-through laboratory services for outpatients during the COVID-19 crisis.

The service does not test patients for coronavirus infection, but provides a mechanism for patients with cancer and blood diseases to have laboratory studies for treatment or clinical trial requirements in the safest possible manner. The drive-up laboratory sites meet the requirements of the state and local governments’ shelter-in-place orders.

At both Springfield Clinic (Springfield, IL; Preet P. Singh, Sub-PI for Disparities and Cancer Care Delivery Research) and Missouri Baptist Medical Center (St. Louis, MO; Bryan A Faller, principal investigator), upon arrival, the patient drives into a designated parking area, calls the registration area and registers for the visit by telephone.

A phlebotomist is sent to the patient’s vehicle and performs the blood draw with the patient’s arm extended through the window. After the drive-through visit, the patient obtains results and further instructions by telephone or via the patient portal.

Springfield Clinic has developed an educational video for patients, describing the service. The service has been popular at both NCORP sites and may be a model for patient-centered service after the pandemic subsides.

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login